Phosphoramidate derivatives of hydroxysteroids as inhibitors of prostate-specific membrane antigen

15Citations
Citations of this article
20Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Prostate-specific membrane antigen (PSMA) is a membrane-bound cell surface peptidase which is over-expressed in prostate cancer cells. The enzymatic activities of PSMA are understood but the role of the enzyme in prostate cancer remains conjectural. We previously confirmed the existence of a hydrophobic binding site remote from the enzyme's catalytic center. To explore the specificity and accommodation of this binding site, we prepared a series of six glutamate-containing phosphoramidate derivatives of various hydroxysteroids (1a-1f). The inhibitory potencies of the individual compounds of the series were comparable to a simple phenylalkyl analog (8), and in all cases IC50 values were sub-micromolar. Molecular docking was used to develop a binding model for these inhibitors and to understand their relative inhibitory potencies against PSMA. © 2007 Elsevier Ltd. All rights reserved.

Cite

CITATION STYLE

APA

Wu, L. Y., Do, J. C., Kazak, M., Page, H., Toriyabe, Y., Anderson, M. O., & Berkman, C. E. (2008). Phosphoramidate derivatives of hydroxysteroids as inhibitors of prostate-specific membrane antigen. Bioorganic and Medicinal Chemistry Letters, 18(1), 281–284. https://doi.org/10.1016/j.bmcl.2007.10.096

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free